MENU
+Compare
IPHA
Stock ticker: NASDAQ
AS OF
Jul 25 closing price
Price
$2.03
Change
-$0.00 (-0.00%)
Capitalization
193.36M

IPHA Innate Pharma SA Forecast, Technical & Fundamental Analysis

Innate Pharma SA is a clinical-stage biotechnology company... Show more

IPHA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for IPHA with price predictions
Jul 25, 2025

IPHA's RSI Oscillator ascends from oversold territory

The RSI Oscillator for IPHA moved out of oversold territory on July 10, 2025. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 22 similar instances when the indicator left oversold territory. In of the 22 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on July 18, 2025. You may want to consider a long position or call options on IPHA as a result. In of 114 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for IPHA just turned positive on July 15, 2025. Looking at past instances where IPHA's MACD turned positive, the stock continued to rise in of 50 cases over the following month. The odds of a continued upward trend are .

IPHA moved above its 50-day moving average on July 23, 2025 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where IPHA advanced for three days, in of 219 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IPHA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

IPHA broke above its upper Bollinger Band on July 23, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for IPHA entered a downward trend on July 21, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. IPHA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (17.986) is normal, around the industry mean (18.028). P/E Ratio (0.000) is within average values for comparable stocks, (59.593). IPHA's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.512). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (11.074) is also within normal values, averaging (278.844).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IPHA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
IPHA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

IPHA is expected to report earnings to fall 73.33% to -7 cents per share on September 15

Innate Pharma SA IPHA Stock Earnings Reports
Q2'22
Est.
$-0.08
Q4'24
Beat
by $0.10
Q2'23
Beat
by $0.16
The last earnings report on March 27 showed earnings per share of -30 cents, beating the estimate of -40 cents. With 3.49K shares outstanding, the current market capitalization sits at 193.36M.
A.I. Advisor
published General Information

General Information

a biopharmaceutical company, which focuses on discovering and developing therapeutic antibodies that harness the innate immune system to improve cancer treatment

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
117, Avenue de Luminy
Phone
+33 430303030
Employees
211
Web
https://www.innate-pharma.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
VEOEY18.060.07
+0.39%
Veolia Environnement
STBI19.070.07
+0.37%
Sturgis Bancorp, Inc.
BCHHF495.77N/A
N/A
Bucher Holding AG
HOIEF12.44N/A
N/A
Hosiden Corporation
UTRX0.03N/A
N/A
Unitronix Corp.

IPHA and Stocks

Correlation & Price change

A.I.dvisor tells us that IPHA and TECH have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that IPHA and TECH's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IPHA
1D Price
Change %
IPHA100%
-0.23%
TECH - IPHA
29%
Poorly correlated
+0.53%
QSI - IPHA
27%
Poorly correlated
-2.53%
ENTA - IPHA
25%
Poorly correlated
+0.82%
NAUT - IPHA
24%
Poorly correlated
-0.41%
SVRA - IPHA
24%
Poorly correlated
+1.18%
More